PPD Named Best Contract Research Organization At VIE Awards

Recognized for industry leadership at World Vaccine Congress

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced it was named the Best Contract Research Organization (CRO) at the 9^th Vaccine Industry Excellence Awards at the World Vaccine Congress 2016. The ViE awards celebrate the outstanding achievements of leaders who continually set standards of excellence and advocacy in the vaccine industry.

“We are honored to receive this award acknowledging PPD’s contributions in helping our customers bring life-changing vaccines to patients more quickly and with the highest standards of quality”

“We are honored to receive this award acknowledging PPD’s contributions in helping our customers bring life-changing vaccines to patients more quickly and with the highest standards of quality,” said Bill Sharbaugh, PPD’s chief operating officer. “PPD has more than 25 years of experience in providing a full range of vaccine testing services. This honor recognizes the expertise of our dedicated team members, who are experts and thought leaders in their individual disciplines and involved in establishing best practices for national and international regulatory organizations.”

PPD’s service offerings span the value chain of clinical research, with integrated Phase I-IV services and PPD^® Laboratories, offering the most comprehensive lab services available in the industry.

PPD Laboratories’ vaccines sciences lab has worked on 12 vaccines approved by regulators and is a leader in comprehensive development and testing services of vaccines. With state-of-the-art facilities and instrumentation, PPD’s vaccine sciences lab helps customers realize the highest scientific standards for their programs, with a focus on cost efficiencies to speed the introduction of life-changing vaccines.

The World Vaccine Congress is an annual gathering of the global vaccine industry to discuss commercial and scientific issues involving regulation, strategy, manufacturing, trials, partnering, influenza, cancer, emerging diseases and veterinary vaccines.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 15,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about its award-winning vaccine services contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.